The phenomenology and treatment of interferon-induced depression.
Level 5 - mechanism / opinion, no new human data
Narrative literature review without systematic review methodology or meta-analysis
PubMed 15488246 · doi:10.1016/j.jad.2004.04.002
What was done
The authors conducted a narrative literature search reviewing the frequency, clinical characteristics, risk factors, potential biochemical mechanisms, and management strategies for depression induced by interferon (IFN) therapy, specifically IFN-alpha, IFN-beta, and IFN-gamma across conditions such as hepatitis C, malignancies, and multiple sclerosis.
What was found
The abstract provides no numerical data, incidence rates, or effect sizes. Qualitatively, the review found that depressive symptoms are common during IFN-alpha therapy and often lead to dose reduction, drug discontinuation, or initiation of psychopharmacologic agents. Depressive symptoms typically resolve following completion of therapy but can recur with dose increases. The link between depression and IFN-beta or IFN-gamma therapy remains less clearly established.
Why it matters
It emphasizes the psychiatric risks of cytokine-based therapies and provides a rationale for baseline screening, routine monitoring with depression rating scales, and early antidepressant treatment to help patients complete necessary antiviral or antineoplastic regimens.
Limits
The abstract reports no search criteria, databases queried, study count, or quantitative summary metrics. As a narrative review, it lacks formal quality assessment of included literature and does not differentiate evidence strength across distinct underlying disease populations.
Cited by
- supports The vast majority of individuals who develop depression during interferon treatment recover completely within a couple of weeks of stopping the medication.